title: [Dalbavancin breakpoints and recommendations for in vitro study of its activity].
abstract: Dalbavancin is a semisynthetic lipoglycopeptide approved for the treatment of acute skin and soft tissue infections due to Gram-positive microorganisms susceptible to this antimicrobial agent. The FDA (Food and Drug Administration) and the EUCAST (European Committee on Antimicrobial Susceptibility Testing) have established clinical breakpoints to interpret the results of the antibiogram (expressed as MIC [minimum inhibitory concentration]) with approved doses (1g intravenously [IV] followed by 0.5g IV at day 8 or 1.5g IV in a single dose). The EUCAST has also determined PK/PD (pharmacokinetic/pharmacodynamic) breakpoints -susceptible, ≤ 0.25mg/L; resistant, > 0.25mg/L-, established recommendations for in vitro susceptibility testing (addition of polysorbate-80 to the growth media) and subrogate values based on the vancomycin-susceptible category to interpret dalbavancin susceptibility in the absence of in vitro study of this antimicrobial.
authors.affiliation: Servicio de Microbiología, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, España; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, España. Electronic address: rafael.canton@salud.madrid.org.
authors.forename: Rafael
authors.initials: R
authors.lastname: Cantón
authors.affiliation: Servicio de Microbiología, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, España; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, España.
authors.forename: María
authors.initials: M
authors.lastname: Díez-Aguilar
authors.affiliation: Servicio de Microbiología, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, España; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, España.
authors.forename: María Isabel
authors.initials: MI
authors.lastname: Morosini
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D006801:Humans; D008826:Microbial Sensitivity Tests; D017334:Teicoplanin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; C469289:dalbavancin
keywords: Breakpoints; Dalbavancin; Dalbavancina; Lipoglucopéptidos; Lipoglycopeptides; Punto de corte; Subrogate value; Valor subrogado